Replies to post #13093 on Penny Stock Tweets

[j$tops]

Agreed 100%!!!

PST IS the Best Resource for ALL Your OTC Market DD ~ AND ~ It's Getting BETTER!!!

See What Newsletters Are Out On Your Stock AND Track How They Are Doing ;)

http://www.pennystocktweets.com/news_letters

[Drugdoctor]

b]COPI .02-Betting on Success – Ambitious Goals for 2013
Following an aggressive operational launch in March 2013, SeanieMac has set an ambitious agenda. The Company‘s 2013 goals include:

Capture one to two percent of $3.2 billion Irish online gambling market share. One in three Irish adults wager regularly, at ~50 Euros per week on average. To achieve just the one percent target, SeanieMac need only convert 10,000 bettors, or two tenths of one percent of the entire Irish population.

Reach positive cash flow. The company targets reaching positive cash flow by year end.

Build the management team. A strong team is already in place, and the Company will announce added veteran industry executives to management, the Board of Directors and an Advisory Board.

Stay at forefront of technology. Grow and evolve the technology platform to capitalize on the latest innovations ensuring the most robust offering for SeanieMac customers. Part of this strategy includes producing a mobile device app shortly that will enable customers to wager from smart phones and tablets.

Raise growth capital. As a public company, SeanieMac has a lower cost of capital. When the time is right, the Company will raise capital to fund future growth.

Aggressive Marketing Strategy. In addition to the multi-media blitz planned for its February launch, other marketing campaigns will include social and conventional media, TV, radio, print, web-based and public relations, advertising and cooperative marketing in 2013.

Form Strategic Alliances. These may include joint ventures, acquisitions and co-marketing agreements with key hospitality, pub, travel, tourism and other associated industry companies.

Communicate Proactively. Implementation of an investor relations program to keep shareholders informed and to communicate proactively with Wall Street.

[Drugdoctor]

ELTP .1069-DRUG-LAUNCH-NEWS-OUT!!!Elite-Pharmaceuticals,-Inc.-Announces-First-Shipment-of-Generic-Naltrexone-Hydrochloride

Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the initial shipment of naltrexone hydrochloride 50 mg tablets under the License, Manufacturing and Supply Agreement with its sales and marketing partner, triggering a milestone payment. Elite's sales and marketing partner will distribute the product as part of a multi-product distribution agreement.

Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence. For the calendar year 2012, Revia and its generic equivalents had total U.S. sales of approximately $16 million according to IMS Health Data.

"With the shipment of naltrexone, Elite has now launched seven products in less than two and a half years," commented Nasrat Hakim, Elite's President and CEO. "The Company has executed the strategic plan on schedule. This plan now includes an additional thirteen products, eleven of which are approved, and are prioritized for commercialization pending manufacturing site transfer."

About Elite Pharmaceuticals, Inc.

Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products. Elite's strategy includes assisting partner companies in the life cycle management of products to improve off-patent drug products and developing generic versions of controlled release drug products with high barriers to entry. Elite has seven commercial products currently being sold, eleven approved products pending manufacturing site transfer and two additional products under review pending approval by the FDA. Elite's lead pipeline products include abuse resistant opioids utilizing the Company's patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain, which address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse. Elite also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.) and has partnered with Mikah Pharma to develop a new product, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the United States market and its territories. Elite operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, NJ.

[$Pistol Pete$]

I marked this board and looks like very good traders here

$Pistol Pete$

[BottomBounce]

$MJNA moving into GREEN into #POWERHOUR from a red month. #Oversold #Undervalued #CBD #Hemp #Cannabidiol #Stock

[BottomBounce]

$AMRS $GEVO Stocks Hitting 52-Week Lows

[BottomBounce]

$LEXG > Tesla Shakes Up Market for Lithium, Other Metals - ‘In order to produce half a million cars a year…we would basically need to absorb the entire world’s lithium-ion production,’ Elon Musk said in March http://www.wsj.com/articles/how-lithium-defied-the-global-commodities-rout-1462450790

[BottomBounce]

$AMRS -long time divergence.

[BottomBounce]

$AMRS Working with U.S. Department of Defense Advanced Research Projects Agency (DARPA), Amyris is encoding DNA to create high performance materials to meet the needs of a growing world.

These advanced technologies developed under the DARPA Living Foundries program are leading the synthetic biology industrial revolution that drives a 350 billion dollar bioeconomy.

https://amyris.com/collaborations/darpa/



***** AMRS working with DAPRA same agency that makes these guys: